Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Launch Date/Release: June 12, 2026

Expiration Date: May 31, 2027

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Launch Date/Release: June 12, 2026

Expiration Date: May 31, 2027

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Launch Date/Release: June 12, 2026

Expiration Date: May 31, 2027

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies.

Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC.

Launch Date/Release: June 3, 2026

Expiration Date: May 31, 2027

FACULTY

Kris V. Kowdley, MD, AGAF, FAASLD, FACG, FACP

Liver Institute Northwest

Director, Velocity Clinical Research

Medical Director and Senior Scientific Advisor

Washington State University

Elson S. Floyd College of Medicine – Professor

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies.

Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC.

Launch Date/Release: June 3, 2026

Expiration Date: May 31, 2027

FACULTY

Kris V. Kowdley, MD, AGAF, FAASLD, FACG, FACP

Liver Institute Northwest

Director, Velocity Clinical Research

Medical Director and Senior Scientific Advisor

Washington State University

Elson S. Floyd College of Medicine – Professor

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides synthesis of key findings, highlight their relevance across pediatric and adult care, and frame practical considerations for patient assessment and longitudinal management.

Launch/Release Date: April 24, 2026

Activity Expiration Date: March 31, 2027

FACULTY

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics

Director, Adult Neurofibromatosis Clinical Program

Division of Oncology, Sarcoma Section

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Launch/Release Date: April 23, 2026

Activity Expiration Date: March 31, 2027

FACULTY

James F. Howard, Jr., MD, FAAN

Professor of Neurology, Medicine & Allied Health

Director, Myasthenia Gravis Clinical Trials and Translational Research Program

The University of North Carolina at Chapel Hill

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Launch/Release Date: October 16, 2025

Activity Expiration Date: September 30, 2026

FACULTY

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics Director

Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.